Skip to main navigation Skip to search Skip to main content

Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.

  • Maria Gabriella Ferrandina
  • , Manuela Ludovisi
  • , Giacomo Corrado
  • , Vito Carone
  • , Vanda Salutari
  • , Marco Petrillo
  • , Giovanni Scambia

Research output: Contribution to journal › Article › peer-review

Original languageEnglish
Pages (from-to)187-193
Number of pages7
JournalGynecologic Oncology
Publication statusPublished - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • CA125
  • Ovarian cancer
  • prognostic role
  • response to chemotherapy

Cite this